Clinical Trial

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-27; most recent amendment 2025-08-30.
Status change: Not Yet Recruiting → Recruiting 2025-08-30
Trial Details
NCT Number NCT06803030
Lead Sponsor Bir Hospital
Collaborators: Nepal Health Research Council
Conditions Ureteral Stent-Related Symptom
Enrollment 189 participants
Start Date 2025-08-30
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08